The next one reshaping your market is already in the pipeline. Oncalix decodes two decades of launch and expansion patterns into competitive intelligence to stay ahead of it.
Pipeline databases track what's in development. Claims data measure what's already happened. Between them is an 18–24 month window where pipeline events are knowable but their commercial impact isn't being modeled — and that's when commercial teams are making their most consequential decisions. Oncalix operates in that gap — translating clinical and regulatory events into structured competitive intelligence that commercial teams can act on.
Identifies historical approvals with matching competitive and clinical profiles to predict your commercial trajectory, with full expansion chain analysis across indications.
Detects and monitors competitive threats, classifies them by displacement risk, and continuously alerts when regulatory events shift your competitive landscape.
Narrows from total incidence through biomarker prevalence, therapy-line distribution, CDx testing rates, and competitive displacement to calculate the patients your drug can actually reach.
We'll walk you through a relevant example tailored to your therapeutic area and competitive landscape.
Every Oncalix analysis is built on CORE™ — our Curated Oncology Registry of Evidence. Unlike drug-level databases, CORE treats each FDA approval as a separate competitive entity. Pembrolizumab isn't one record — it's more than 40 distinct approval events across oncology, each with its own clinical data, competitive context, and commercial trajectory. That architectural decision changes everything.
Identifies historical oncology approvals whose clinical data, competitive context, and market dynamics most closely match your asset — using CORE's Regimen Fingerprint system. Provides launch context and addressable population benchmarks for each analogue. Also maps historical expansion chain pathways — which indications analogues expanded into after initial approval, in what sequence, and what outcomes resulted.
ECHO is not a therapeutic area landscape report. It's structural matching with outcome linkage across indications.
Maps every competitive asset in your indication setting, classifies each by displacement risk, and continuously alerts you when regulatory events shift your competitive landscape. AI-driven surveillance scans regulatory filings, clinical trial registries, conference abstracts, and guideline updates — surfacing relevant changes automatically for expert review before client alerting.
FLARE is not a pipeline tracker. It's a patient-flow impact model with continuous regulatory surveillance.
Builds the patient funnel from real-world data — SEER epidemiology, biomarker prevalence, CDx testing rates, therapy-line distribution, and competitive displacement — to calculate the patients your drug can actually reach. Includes sensitivity modelling showing how your addressable population changes under different testing, competitive, and guideline scenarios.
SCOPE is not a top-down epidemiology forecast. It's a bottom-up patient flow model built from evidence at every layer.
Every Oncalix engagement includes continuous updates. Your competitive intelligence doesn’t expire when the initial project ends.
The engagement tells you where you stand today. Continuous monitoring makes sure you’re never surprised by what changes tomorrow.
Every engagement is tailored to a specific asset and competitive context. These scenarios illustrate the types of questions Oncalix is built to answer.
You've just received your first FDA approval in a 2L setting. The board wants an expansion roadmap: which indications to pursue next, in what order, and what the commercial upside looks like at each step. Your team has hypotheses but no structured framework for evaluating them.
ECHO maps your approval profile against historical drugs with similar first approvals — revealing the expansion chains that generated the highest cumulative commercial value.
SCOPE sizes the addressable patient population at each potential expansion step, so you can prioritize by actual patient volume, not assumed market size.
FLARE overlays pipeline competition on each expansion path — showing which directions are open and which are closing.
Among historical analogues with your competitive profile, the most successful expansion sequence was adjuvant followed by 1L combination. But FLARE identifies two Phase 3 competitors targeting your highest-value expansion path — the window may be 3 years, not 5.
Your BD team is evaluating an in-licensing opportunity: a Phase 3 oncology asset in a biomarker-defined subpopulation. The licensor's projections show a $500M peak revenue opportunity. Your team needs to pressure-test that number before committing $200M+ in upfront and milestone payments.
SCOPE builds the real patient funnel — from incidence through biomarker prevalence, testing rates, and competitive displacement — often revealing addressable populations 30–60% below licensor estimates.
ECHO identifies historical approvals with matching clinical profiles and shows their actual commercial trajectories — what revenue analogues actually achieved, not what models predicted.
The licensor's 12,000-patient addressable estimate becomes 4,200 after accounting for CDx testing rates and 1L competitive displacement. ECHO analogues show peak revenues of $180M–$320M for comparable launches — credible, but materially below the licensor's model.
A competitor just reported positive Phase 3 results at a major medical congress targeting the same 2L patient population as your launched product. Your commercial leadership wants to know — within days, not months — what this means for your franchise and what to do about it.
FLARE immediately classifies the threat type, maps which patient segments are at risk of displacement, and estimates the timeline to regulatory action based on the competitor's clinical profile and designation status.
SCOPE recalculates your addressable population under the new competitive scenario — showing the before-and-after impact on your patient funnel, segment by segment.
The competitor's data is strong in biomarker-positive patients (your 40% of franchise revenue) but weak in biomarker-negative. Displacement risk is concentrated in a single patient stratum. Recommendation: accelerate your biomarker-negative data presentation and reallocate share-of-voice to the segments where your position is defensible.
Have a different scenario? Every engagement starts with your specific asset.
Oncalix was founded on a simple observation: the analytical questions driving oncology launch decisions are structurally identical across drugs and tumor types, yet every company pays to answer them from scratch. We built the system that changes that.
Every Oncalix output follows the same rigorous pipeline — combining AI-powered data extraction with domain expert verification to produce intelligence you can trust.
FDA labels, NCCN guidelines, SEC filings, clinical trial registries, congress presentations — structured extraction from authoritative sources
Large language models parse, normalize, and structure data into CORE’s 100+ field architecture at the individual approval level
Every extracted data point is validated by domain experts with 20 years of oncology commercial strategy experience
SCOPE, FLARE, and ECHO products generate intelligence outputs — patient funnels, threat maps, expansion chains — ready for decision-making
Built with AI. Verified by Experts.
CORE is built through a rigorous process that combines AI-powered data extraction, pattern recognition, and cross-referencing with expert curation by oncology commercial strategists. Every data point is AI-surfaced and human-verified. Every analytical relationship — Regimen Fingerprints, expansion chain links, threat classifications — is expert-validated before it enters the registry.
The result is intelligence you can trust at the speed only technology can deliver. AI handles the scale. Experts ensure the accuracy. You get both.
Twenty years of US oncology commercial consulting — building the competitive intelligence, launch analytics, and patient flow models that pharma companies use to make their biggest commercial decisions. VP Analytics at a leading consulting firm. Director and Senior Director at IQVIA, where the work touched every major oncology launch in the US market.
After two decades of building these analyses one-off for the largest pharma companies, the pattern became clear: the analytical framework itself was the product. The questions were always the same — which pipeline drugs threaten my patients, how large is my real addressable population, and which historical launches predict mine? Different drug, different tumor type, same analytical architecture.
Oncalix is that architecture — structured, reproducible, and accessible to any oncology commercial team, regardless of size.
Follow Oncalix on LinkedInWe'll walk you through a relevant example tailored to your therapeutic area and competitive landscape. No slide deck. No generic demo. A focused conversation about what Oncalix intelligence would look like for your specific product.